title: New insights for pelvic radiation disease treatment: Multipotent stromal cell is a promise mainstay treatment for the restoration of abdominopelvic severe chronic damages induced by radiotherapy.
abstract: Radiotherapy may induce irreversible damage on healthy tissues surrounding the tumor. It has been reported that the majority of patients receiving pelvic radiation therapy show early or late tissue reactions of graded severity as radiotherapy affects not only the targeted tumor cells but also the surrounding healthy tissues. The late adverse effects of pelvic radiotherapy concern 5% to 10% of them, which could be life threatening. However, a clear medical consensus concerning the clinical management of such healthy tissue sequelae does not exist. Although no pharmacologic interventions have yet been proven to efficiently mitigate radiotherapy severe side effects, few preclinical researches show the potential of combined and sequential pharmacological treatments to prevent the onset of tissue damage. Our group has demonstrated in preclinical animal models that systemic mesenchymal stromal cell (MSC) injection is a promising approach for the medical management of gastrointestinal disorder after irradiation. We have shown that MSCs migrate to damaged tissues and restore gut functions after irradiation. We carefully studied side effects of stem cell injection for further application in patients. We have shown that clinical status of four patients suffering from severe pelvic side effects resulting from an over-dosage was improved following MSC injection in a compationnal situation.
authors.affiliation: Alain Chapel, Sabine Francois, Marc Benderitter, Radiological Protection and Human Health Division, Institute of Radiological Protection and Nuclear Safety, PRP-HOM/SRBE/Laboratory of Radiopathology and Experimental Therapies, 92262 Fontenay-aux-Roses, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Chapel
authors.forename: Sabine
authors.initials: S
authors.lastname: Francois
authors.forename: Luc
authors.initials: L
authors.lastname: Douay
authors.forename: Marc
authors.initials: M
authors.lastname: Benderitter
authors.forename: Jan
authors.initials: J
authors.lastname: Voswinkel
keywords: Cell therapy; Clinical trial; Irradiation; Mesenchymal stem cells; Multipotent stromal cells; Radiotherapy; Stem cells